HeartBeam Inc. (NASDAQ: BEAT), a medical technology company developing advanced electrocardiogram (ECG) solutions, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. The company secured the second position worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. This recognition underscores HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
The ranking highlights the rapid maturation of HeartBeam’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. By doing so, HeartBeam is addressing one of modern medicine’s most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, with ischemia assessment as a future goal.
HeartBeam is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be deployed wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement.
To view the full article, visit this link. For more information about HeartBeam, visit the company’s website. The latest news and updates relating to BEAT are available in the company’s newsroom at this location.
